AdoShell® Islet Cell Therapy
Type 1 Diabetes
PreclinicalPlatform Development
Key Facts
About Adocia
Adocia is a clinical-stage biotechnology company focused on developing innovative formulations and delivery systems for metabolic diseases, primarily diabetes and obesity. The company's strategy is built on four proprietary technology platforms (BioChaperone®, AdoShell®, AdOral®, AdoXLong) designed to enhance the efficacy and delivery of peptides, proteins, and cell therapies. Key achievements include advancing a Phase 3 ultra-rapid insulin and securing partnerships with major pharmaceutical firms like Eli Lilly and Tonghua Dongbao. Adocia's business model involves licensing out its validated assets post-proof-of-concept to global partners for development and commercialization.
View full company profileOther Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |